UPDATE: Goldman Sachs Raises PT on Tenet Healthcare to $7

Goldman Sachs is out with its report today on Tenet Healthcare THC, raising its PT from $6.50 to $7. In its report, Goldman Sachs writes, "THC trades at 5.4X 2011 EV/EBITDA, a discount of 6% and 35% to its peers and 10-year median. Our 12-month price target is now $7.00 (up from $6.50), driven by higher 2011E EBITDA. As before, our target is based on 6X EV/EBITDA (80%) and $9 DCF (20%)." Goldman Sachs maintains Neutral on THC. Shares of THC closed Tuesday at $5.10.